Growth hormone as a treatment for gastroparesis
Tests low-dose growth hormone for symptoms in adults with gastroparesis.
Key facts
- Who runs it
- Mayo Clinic
- Where
- Phoenix and Scottsdale, United StatesSee the 2 sites
- Trial code
- Registry title
- Growth Hormone for the Treatment of Gastroparesis
- Status
- Recruiting
- Phase
- Early phase 1
- People taking part
- 10 people, planned
- Started
- 22 Oct 2024
- Expected to end
- Dec 2027
- Type of study
- Interventional
- Treatments tested
- Growth Hormone
- Record updated
- 16 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with gastroparesis (slow stomach emptying) whose symptoms have not improved enough with standard treatment. It tests low-dose Growth Hormone.
- Age
- 18 to 65 years
- Sex
- All sexes can join.
- Disease stage
- Symptoms for more than 6 months. Gastroparesis Cardinal Symptom Index (GCSI) score of more than 21.
- Earlier treatment
- Standard treatment has not helped enough. People who used GH therapy before cannot join.
- Biomarker or test result
- People with low serum IGF1 for their age cannot join.
Main reasons for not taking part
- Diabetes
- Growth hormone deficiency, pituitary or hypothalamus disease, or pituitary surgery
- Pregnancy or breastfeeding, or women taking estrogen by mouth
- History of solid cancer, heart artery disease, blood clots, sarcoidosis or thyroid nodules
- Obesity (BMI > 30)
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Symptoms > 6 months that have not responded satisfactorily to standard treatment
- For gastroparesis: Gastroparesis Cardinal Symptom Index (GCSI) score of >21
Who cannot take part
- Prior use of GH therapy
- Known history of GH deficiency, hypothalamic or pituitary disease
- Diabetes
- History of malignant solid tumors
- Obesity (BMI > 30)History of coronary and thromboembolic diseases
- History of sarcoidosis
- History of pituitary surgery
- History of thyroid nodules
- Any other condition, which in the opinion of the investigator would impede compliance or hinder completion of the study
- Failure to give informed consent
- Age-adjusted low serum IGF1
- Women on oral estrogen therapy6
- Pregnancy or nursing
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Where in United States
- Mayo ClinicPhoenix, United StatesContact: Guillermo Barahona Hernandez, Sr. Progam CoordiantorTaking people
- Mayo Clinic in ArizonaScottsdale, United StatesContact: Tisha Lunsford, MDTaking people
About the trial
What the trial wants to find out
The purpose of this study is to determine whether treatment with Growth Hormone results in symptomatic improvement in patients with gastroparesis.
The group in the trial
- Treatment GroupTreatment being tested
Patients with Gastroparesis
Treatment: Growth Hormone
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Low-dose Growth Hormone for the Treatment of Gastroparesis
- Plain-language title
- Growth hormone as a treatment for gastroparesisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT06803589, who can take part
- Record updated
- 16 April 2026